Daiichi Sankyo begins patient dosing in QuANTUM-Wild phase 3 trial of Vanflyta in newly diagnosed FLT3-ITD negative AML: Tokyo Thursday, December 12, 2024, 12:00 Hrs [IST] The fir ...

Daiichi Sankyo has announced the dosage of the first subject in the randomised Phase III QuANTUM-Wild trial of oral Vanflyta ...

IonQ , a leader in the quantum computing and networking industry, will highlight the transformative power of quantum computing for the future of business at Q2B24 Silicon Valley. At Q2B24, IonQ will ...

The first patient has been dosed in the QuANTUM-Wild phase 3 trial evaluating Daiichi Sankyo’s (TSE: 4568) VANFLYTA® ...

One of the runways at Vancouver International Airport will be closed for several days after a jet carrying Amazon packages overran it Tuesday morning. The Prime Air Boeing 767-300 operated by ...

Blood cancer sufferers across the country are celebrating after two new drugs were approved on the NHS in Scotland. Regulators in Scotland, the Scottish Medicines Consortium (SMC), gave the green ...

Join Edinburgh Live's Whatsapp Community here and get the latest news sent straight to your messages. Daiichi Sankyo’s drug, quizartinib (Vanflyta) has also been recommended by the SMC for acute ...

Last year, Nkarta was celebrating data which showed that its natural killer (NK) cell therapy for acute myeloid leukaemia (AML) was showing remarkable efficacy in hard-to-treat patients, but its ...

Shares in Nkarta more than doubled yesterday on the results of early-stage clinical that suggested it could be on to a winner with its natural kill (NK) cell therapy platform. The two phase 1 ...